Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
13
3
3
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
7.7%
1 terminated/withdrawn out of 13 trials
87.5%
+1.0% vs industry average
54%
7 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Role: collaborator
VTE Prevention Following Total Hip and Knee Arthroplasty
Role: collaborator
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
Role: collaborator
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
Role: collaborator
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study
Role: collaborator
Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention
Role: collaborator
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
Role: collaborator
Improving Emergency Department Testing for Deep Vein Thrombosis
Role: collaborator
TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study
Role: collaborator
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Role: collaborator
Adjust-Unlikely PE
Role: collaborator
WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism
Role: collaborator
Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
Role: collaborator
All 13 trials loaded